Skip to content
    SOLV
    Earnings call· Jun 2026(Q2 FY26)

    Solventum Q2 FY26 earnings call SOLV

    Aug 5, 2026 Source

    Executive summary

    Solventum Q2 FY26 — Strong Performance and Strategic Portfolio Optimization

    Solventum delivered a strong second quarter, surpassing top and bottom-line expectations, driven by solid execution and momentum across all segments. The company is nearing completion of its 3M separation, which is expected to improve free cash flow and focus resources on growth. A significant strategic move was announced with the intent to separate the Health Information Systems (HIS) business to unlock shareholder value and sharpen the company's focus on MedTech, with an Investor Day planned for Q1 next year to detail the post-HIS long-range plan.

    Highlights

    5

    • Organic sales growth of 9.5% reported, or 4% normalized for ERP advanced orders, exceeding expectations.

    • Adjusted EPS of $2.55, including $0.34 from advanced orders and $0.48 from tariff refund, ahead of expectations.

    • Gross margins increased by 410 basis points to 60.1% (55.6% excluding tariff refund), driven by programmatic savings.

    • Acera acquisition continues to perform strongly with over 40% year-over-year revenue growth and over 80% gross margin.

    • Share repurchase program accelerated, with $288 million used to repurchase nearly 4 million shares in the quarter.

    Concerns

    3

    • ERP advanced orders of approximately $125 million in Q2 will mostly reverse in Q3, leading to an expected Q3 sales decline of -3% to -4%.

    • Tariff impact of 150 basis points on gross margins, partially offset by programmatic savings.

    • Litigation costs of $157 million (net of $55 million insurance proceeds) recorded, excluded from non-GAAP results.

    Guidance & targets

    13
    CategoryTargetConfidence
    Full-year 2026 Organic Sales Growth
    2.5% to 3%
    high materiality
    High
    Full-year 2026 Organic Sales Growth (ex-SKU exits)
    3.5% to 4%
    high materiality
    High
    Full-year 2026 Currency Impact on Sales Growth
    approximately 100 basis points favorable
    medium materiality
    High
    Full-year 2026 Operating Margin
    22.2% to 22.7%
    high materiality
    High
    Full-year 2026 Nonoperating Expenses
    approximately $300 million
    medium materiality
    High
    Full-year 2026 Effective Tax Rate
    19.5% to 20.5%
    medium materiality
    High
    Full-year 2026 Tariff Impact
    neutral impact
    medium materiality
    High
    Full-year 2026 Earnings Per Share
    $7.10 to $7.20
    high materiality
    High
    Full-year 2026 Free Cash Flow
    $200 million to $300 million
    high materiality
    High
    Q3 2026 Sales Impact from Advanced Orders Reversal
    minus 3% to minus 4% range
    high materiality
    High
    Q3 2026 EPS Impact from Advanced Orders Reversal
    minus $0.34
    high materiality
    High
    Q4 2026 Sales Growth Expectation
    3% to 4% range
    medium materiality
    High
    2027 Organic Sales Growth (ex-SKU exits)
    accelerate past 3.5% to 4%
    high materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    MedSurg
    Growth driven by ERP advanced orders, particularly in Infection Prevention and Surgical Solutions, and continued benefit in Advanced Wound Care from performance and advanced orders. Acera contributed $32 million to reported sales.
    ERP advanced orders contribution: 700 basis pointsAdvanced Wound Care organic growth: 7.1%Infection Prevention and Surgical Solutions organic growth: 10.1%
    		$1.4B8.9% organic——
    Dental Solutions
    Underlying performance benefited from innovative new product launches, alongside a significant contribution from ERP advanced orders.
    ERP advanced orders contribution: approximately 10 percentage points
    		$396M15.2% organic——
    Health Information Systems
    Growth driven by continued strength in revenue cycle management solutions, supported by healthy customer retention and ongoing commercial execution.
    		$354M5.4% organic——

    Operational metrics

    33
    Sales
    $2.2B2.2% reported growth
    Q2 FY26

    Total sales for the quarter.

    Organic Sales Growth
    9.5%YoY
    Q2 FY26

    Reported organic growth.

    Organic Sales Growth (normalized)
    4%
    Q2 FY26

    Normalized for ERP advanced orders and SKU rationalization headwinds.

    Foreign Currency Impact on Reported Growth
    100benefit
    Q2 FY26

    Benefit to reported growth.

    Acquisitions and Divestitures Net Impact on Reported Growth
    830headwind
    Q2 FY26

    Net impact on reported growth.

    ERP Advanced Orders
    $125M
    Q2 FY26

    Planned temporary advanced ordering as mitigation to ERP cutovers.

    Pricing
    +/- 1%
    Q2 FY26

    Remained within expected range.

    SKU Rationalization Plan Headwinds
    100
    Q2 FY26

    Partial offset to ERP advanced orders in normalized organic growth.

    Acera Growth Contribution to Total Growth
    40
    Q2 FY26

    Would have added to total growth if included in organic growth calculation.

    Acera Growth Contribution to MedSurg
    70
    Q2 FY26

    Would have added to MedSurg growth if included in organic growth calculation.

    Acera Revenue Growth
    48%YoY
    Q2 FY26

    Driven by innovative synthetic tissue matrix technology.

    Acera Gross Margin
    80%
    Q2 FY26

    Gross margin for the Acera business.

    Gross Margins
    60.1%up 410 bps YoY
    Q2 FY26

    Includes a one-time tariff refund benefit of $100 million.

    Gross Margins (ex-tariff refund)
    55.6%down 40 bps YoY
    Q2 FY26

    Consistent with expectations.

    Operating Expenses
    $701Mdown $35M YoY
    Q2 FY26

    Reduction reflects portfolio moves, cost discipline, and savings initiatives outpacing investments.

    Operating Income
    $627M
    Q2 FY26

    Total operating income.

    Operating Margin
    28.4%
    Q2 FY26

    Reported operating margin.

    Operating Margin (adjusted)
    21.7%down 20 bps YoY
    Q2 FY26

    Just above the high end of initial full year outlook.

    Nonoperating Expense
    $73M
    Q2 FY26

    Consistent with full year expectations.

    Effective Tax Rate
    20.2%
    Q2 FY26

    Consistent with full year expectations.

    Earnings Per Share (non-GAAP)
    $2.55
    Q2 FY26

    Includes $0.34 from advanced orders and $0.48 from tariff refunds.

    Earnings Per Share (non-GAAP, ex-advanced orders and tariff refund)
    $1.73
    Q2 FY26

    Estimated EPS excluding both advanced orders and tariff refund benefits, ahead of expectations.

    Litigation Costs (GAAP)
    $157M
    Q2 FY26

    Included in GAAP to non-GAAP supplemental schedule and excluded from non-GAAP operating income and EPS.

    Cash and Equivalents
    $403M
    Q2 FY26

    Balance at quarter end.

    Net Debt
    $4.7B
    Q2 FY26

    Balance at quarter end.

    Share Repurchases (Q2)
    $288M
    Q2 FY26

    Under authorized share repurchase program.

    Share Repurchases (YTD)
    $355M
    YTD Q2 FY26

    Combined repurchases in the first two quarters.

    3M Separation Transition Service Agreements Exited
    70%
    Q2 FY26

    Nearing completion of full separation.

    Systems Migrated
    950
    Q2 FY26

    Progress on 3M separation.

    New Product Launches
    almost 20
    future

    Expected launches, including meaningful MedSurg launches in H1 2027 and Dental innovations later this year.

    IV Site Management Market Opportunity
    $10B
    annual

    IV-related infections impact 2-3 million patients annually, increasing mortality risk by 50%.

    Tegaderm CHG Infection Reduction
    nearly 60%lower infection rates
    ongoing

    Tegaderm CHG is FDA-cleared to reduce catheter-related bloodstream infections.

    Tegaderm CHG Usage Rate
    less than 20%
    current

    Indicates over 80% of the opportunity is still available for this differentiated solution.

    Industry KPIs

    7
    MetricValueDetails
    Tariff impactNeutral impact
    Pricing realized price+/- 1%%
    New product launch rampAlmost 20 new productsproducts
    Procedure volume growthNo softness observed
    FCF conversion leverage guidanceFY26 FCF: $200M-$300M; Net Debt: $4.7BUSD
    Segment franchise organic growthMedSurg: 8.9% organic; Advanced Wound Care: 7.1% organic; Infection Prevention and Surgical Solutions: 10.1% organic; Dental Solutions: 15.2% organic; Health Information Systems: 5.4% organic%
    Indicated addressable patient population$10BUSD

    Product announcements

    8
    ProductTypeDetails
    V.A.C. Peel and Place dressinglaunch
    Attest sterilization productslaunch
    Tegaderm CHG global expansionexpansion
    ClinPro Clearlaunch
    Filtek Easy Match and Easy Match Flowablelaunch
    Composite warmerlaunch
    Clarity aligner attachmentslaunch
    AI-driven autonomous coding applicationslaunch

    Deals & partnerships

    3
    AceraAcquisition of a company with innovative synthetic tissue matrix technology (Restrata).

    First acquisition for Solventum, integrated and exceeding expectations. Integration activities remain on track with several key system conversions complete.

    Health Information Systems (HIS) businessAdvancing the separation of the Health Information Systems business to maximize value.

    Strategic decision to separate HIS, which is a differentiated, trusted business with a highly resilient financial profile, to better capitalize on AI advancements. Solventum is open to various separation methods (spin or sale) and use of proceeds to maximize value.

    Purification and Filtration businessDivestiture of the Purification and Filtration business.

    Divestiture activities continue to progress according to plan, including transition-related work streams supporting separation.

    Risks & headwinds

    6
    ERP cutover complexity and distractionQ2-Q3 FY26

    Advanced orders of approximately $125 million in Q2 to mitigate disruption; Q3 sales expected to be -3% to -4% due to reversal.

    Mitigation: Planned temporary advanced ordering; nearing completion of ERP cutovers to free up talent and resources.

    SKU rationalization plan headwindsFY26

    Approximately 100 basis points impact on Q2 organic growth.

    Mitigation: Part of a strategic plan, expected to be a 100 basis point impact for the full year, but will not have an impact in 2027.

    Tariff impact on gross marginsQ2 FY26

    150 basis points impact on gross margins (ex-tariff refund).

    Mitigation: Partially offset by programmatic savings and portfolio optimization. Full-year tariff impact now expected to be neutral due to Q2 refund.

    Litigation costsQ2 FY26

    $157 million recorded (net of $55 million insurance proceeds).

    Mitigation: Excluded from non-GAAP operating income and EPS; insurance proceeds received.

    Temporary demands on cash flow from separation activitiesFY26

    Despite strong underlying cash generation, separation-related activities create temporary demands on cash flow.

    Mitigation: Meaningful improvement expected as separation-related costs decline beginning in Q4.

    Potential EPS dilution from HIS separationFuture

    Not quantified, but acknowledged as a factor.

    Mitigation: Company aims to minimize dilution and maximize shareholder value by carefully selecting the separation method and use of proceeds (e.g., share buybacks).

    What to watch in Q3 FY26

    5

    HIS Separation Progress

    Future date, Investor Day in Q1 next year.
    CurrentIntent to separate announced; early in process.
    TargetFurther updates on method, timeline, and financial impact.

    Why it matters

    This is a major portfolio optimization move expected to unlock shareholder value and redefine Solventum as a focused MedTech company.

    We'll update you on the financial impact of the expected separation at a future date.

    Q&A highlights

    6

    Asked about external interest in HIS, the stage of the separation process, and how HIS separation aligns with a 'stronger growth profile' given its current performance.

    Bryan Hanson stated that HIS, despite its strong current performance and growth, has significant untapped potential, especially in AI-driven autonomous coding, which could be better realized with different investment levels and pace of innovation outside Solventum or with a scaled HIT player. He confirmed the company is early in the separation process, driven by the lifting of spin-off barriers and market changes. Inbound interest has been ongoing and is expected to increase.

    “We see significant opportunity. Just think about it. If you think about autonomous coding, as a revolution, if you will, inside of revenue cycle management. It is just beginning. There is no question about that. But to be able to truly maximize it, we're going to have to see a different investment level. We're going to have to see a different pace of innovation.”

    asked by Jason Bednar · answered by Bryan Hanson

    2 min read5 chapters

    Detailed Narrative

    01

    Health Information Systems (HIS) Separation

    Solventum announced its intent to separate the Health Information Systems (HIS) business, aiming to maximize shareholder value. The rationale includes strategic fit, as HIS is believed to create greater value outside Solventum, either independently or with a scale player, especially given rapid AI advancements. The separation will allow Solventum to become a more focused MedTech company, concentrating on MedSurg and Dental. The company is early in the process and open to various separation methods (spin or sale) to maximize value, noting that HIS is not highly integrated with the rest of the business, making separation relatively easier.

    02

    ERP Cutover and 3M Separation Nearing Completion

    The company is in the final steps of its separation from 3M, with the final phases of ERP cutover in motion. Approximately 70% of 200 transition service agreements have been exited, on pace for 90% by year-end 2026. About 950 of 1,200 systems have been migrated, including most ERP implementations. This completion is expected to remove significant complexity, free up talent for innovation and margin expansion, and meaningfully improve free cash flow, transitioning the company from a separation-distracted environment to full operating mode.

    03

    Acera Acquisition Exceeding Expectations

    Acera, Solventum's first acquisition, continues to perform exceptionally well, with year-over-year revenue growth above 40% and gross margin above 80%. The acquisition aligns with Solventum's M&A playbook, focusing on differentiated technology in known spaces with existing customer relationships. The company expects Acera to remain a double-digit grower and increasingly contribute to overall portfolio growth, highlighting the success of its tuck-in acquisition strategy.

    04

    Growth Drivers and Innovation Strategy

    Solventum's strategy is centered on five growth drivers in durable markets with attractive growth and margin profiles, representing a multibillion-dollar opportunity. Innovation and commercial teams are aligned with these drivers. Examples include IV site management (Tegaderm CHG), negative pressure wound therapy (V.A.C. Peel and Place), sterilization assurance (Attest products), core restorative and aesthetics in Dental (ClinPro Clear, Filtek Easy Match), and AI-driven autonomous coding in HIS. The vitality index is improving, with almost 20 new products expected to launch by Q1 2028.

    05

    Market Utilization and Procedure Trends

    Management noted that they are not currently seeing any softness in procedures or business momentum, despite some conflicting reports in the broader market. The company operates across both inpatient and outpatient settings (including ASCs) for many of its MedSurg products, mitigating the impact of any shifts in care settings. This stable market environment, coupled with strong execution, contributes to the company's confidence in its performance.

    AI-generated summary of the company’s earnings call. Not investment advice.